New experimental findings reveal how statin medications may induce stress in vulnerable muscle cells, according to a June 22 study published in Science Advances. The research suggests that these effects could inform future strategies to reduce muscle symptoms without compromising the cardiovascular protection offered by statins.
The study found that statins reduced isoprenoid production, protein prenylation, and yes-associated protein (YAP) signaling. In experimental models, statins also activated nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasomes and promoted nuclear forkhead box O (FOXO) accumulation. These changes increased atrogin-1 levels and led to muscle atrophy and reduced function.
Healthcare providers commonly prescribe statins for people with elevated low-density lipoprotein cholesterol levels to lower the risk of heart attacks and strokes. However, some users experience muscle pain or weakness even when blood tests do not indicate injury. Most prior studies focused on severe complications such as rhabdomyolysis—extensive muscle breakdown—which are rare among statin users.
Researchers developed a model of mild statin-related muscle problems for analysis using mouse muscle cells exposed to lipopolysaccharide (LPS), which primes immune responses. These LPS-primed cells became more sensitive to fluvastatin at clinically relevant doses, showing molecular changes linked with atrophy sooner than unprimed cells. In mice given LPS injections and fed fluvastatin, grip strength declined despite stable overall muscle mass—mirroring mild weakness seen in some human patients taking statins.
Further experiments indicated that the loss of isoprenoids—not just cholesterol reduction—was responsible for activating danger signals in muscles through NLRP3 inflammasome pathways. Restoring isoprenoid levels or inhibiting NLRP3 signaling lessened signs of atrophy in both cell cultures and animal models. Mice lacking NLRP3 showed fewer abnormal fibers after treatment with statins compared to normal mice.
The authors conclude that targeting these specific pathways could help mitigate the risk of muscular side effects while preserving the benefits of cholesterol lowering from statin therapy, if confirmed by further human studies.
